Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001610717-23-000289)

Filing Details

Accession Number:: 0001610717-23-000289
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-19 19:52:07
Reporting Period:: 2023-09-19

Accepted Time:: 2023-09-19 19:52:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1885522	Neumora Therapeutics Inc.	NMRA	Biological Products, (No Disgnostic Substances) (2836)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
318154	Amgen Inc	One Amgen Center Drive Thousand Oaks CA 91320		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-19	33,603,948	$0.00	33,603,948	No	4	C	Direct
Common Stock	Acquisiton	2023-09-19	1,764,705	$17.00	35,368,653	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Preferred Stock	Disposition	2023-09-19	32,754,291	$0.00	32,754,291	$0.00
Common Stock	Series B Preferred Stock	Disposition	2023-09-19	849,657	$0.00	849,657	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.